0000899243-20-032448.txt : 20201202
0000899243-20-032448.hdr.sgml : 20201202
20201202094508
ACCESSION NUMBER: 0000899243-20-032448
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201202
FILED AS OF DATE: 20201202
DATE AS OF CHANGE: 20201202
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: HUTCHISON PATRICK
CENTRAL INDEX KEY: 0001673870
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34236
FILM NUMBER: 201362575
MAIL ADDRESS:
STREET 1: C/O BIOSPECIFICS TECHNOLOGIES CORP
STREET 2: 2 RIGHTER PARKWAY SUITE 200
CITY: WILMINGTON
STATE: DE
ZIP: 19803
FORMER NAME:
FORMER CONFORMED NAME: Hutchison Patrick
DATE OF NAME CHANGE: 20160504
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BIOSPECIFICS TECHNOLOGIES CORP
CENTRAL INDEX KEY: 0000875622
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 113054851
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 35 WILBUR ST
CITY: LYNBROOK
STATE: NY
ZIP: 11563
BUSINESS PHONE: 302-842-8450
MAIL ADDRESS:
STREET 1: 2 RIGHTER PARKWAY, SUITE 200
CITY: WILMINGTON
STATE: DE
ZIP: 19803
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-12-02
1
0000875622
BIOSPECIFICS TECHNOLOGIES CORP
BSTC
0001673870
HUTCHISON PATRICK
C/O BIOSPECIFICS TECHNOLOGIES CORP.
2 RIGHTER PKWY, DE CORP CENTER II
WILMINGTON
DE
19803
0
1
0
0
Chief Financial Officer
Stock Option (Right to Buy)
56.21
2020-12-02
4
D
0
10000
32.29
D
2030-01-06
Common Stock
10000
0
D
Upon the consummation of the merger contemplated by that certain Agreement and Plan of Merger, by and among BioSpecifics Technologies Corp., Endo International plc, and Beta Acquisition Corp., dated October 19, 2020, the stock options, which provided for vesting in four equal annual installments following the grant date (January 6, 2020), were canceled in exchange for a cash payment of $322,900.00, representing the product obtained by multiplying (x) the aggregate number of shares of common stock underlying the stock options by (y) the amount by which the offer price ($88.50) exceeds the per share exercise price of such stock option.
/s/ Patrick C. Hutchison, by Carl A. Valenstein, attorney-in-fact
2020-12-02